Medicines Co. Stock
Your prediction
Pros and Cons of Medicines Co. in the next few years
Pros
?
C******** o* t** e**********
?
S********** s********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Medicines Co. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Medicines Co. | - | - | - | - | - | - | - |
| Repligen Corp. | 0.120% | 2.107% | 3.044% | 14.930% | -12.283% | -21.804% | -40.343% |
| Opko Health Inc. | -2.540% | 12.745% | -12.214% | 8.347% | 5.485% | -29.560% | -60.977% |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co. Ltd. | -0.580% | -1.149% | 8.176% | -14.000% | -12.245% | -36.296% | -21.818% |
Comments
News
Amneal Pharmaceuticals Q2 Earnings Call Highlights
Key Points
- Interested in Amneal Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amneal reported strong Q2 results, with revenue up 10% to $796 million, adjusted EBITDA up 12% to
Meet the Stock That's Obliterating Eli Lilly, Johnson & Johnson, and AbbVie Right Now
Shares of Revolution Medicines (NASDAQ: RVMD), a clinical-stage drugmaker, have gained 132% this year, easily outpacing the returns of leading pharmaceutical companies such as Eli Lilly (NYSE: LLY)
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold
The first GLP-1 medicine was approved in the U.S. in 2005 for the treatment of type 2 diabetes. Since then, breakthroughs have occurred in the field. Medicines in this class are now indicated for